首页> 外文期刊>Journal of biomolecular techniques :JBT. >Locked Nucleic Acid and TaqMan Probes to Detect KRAS Mutations by Droplet Digital PCR in Colorectal Carcinoma Formalin Fixed Paraffin Embedded Tissue Samples
【24h】

Locked Nucleic Acid and TaqMan Probes to Detect KRAS Mutations by Droplet Digital PCR in Colorectal Carcinoma Formalin Fixed Paraffin Embedded Tissue Samples

机译:锁定核酸和TaqMan探针通过液滴数字PCR检测大肠癌福尔马林固定石蜡包埋的组织样品中的KRAS突变

获取原文
       

摘要

BACKGROUND: Metastatic colorectal carcinoma (CRC) tumors with KRAS mutations in exon 2, codons 12 and 13, do not benefit from anti-epidermal growth factor receptor (EGFR) antibody therapy. Current best practice recommends that KRAS mutation analysis be included in patients with CRC as a prerequisite for treatment with cetuximab or panitumumab. We selected 50 CRC formalin fixed paraffin embedded (FFPE) samples to compare a qPCR assay (QIAGEN therascreen? KRAS RGQ PCR Kit) to droplet digital PCR (ddPCR). Wild type and six single nucleotide mutations in KRAS codons 12 and 13 were tested. Methods. DNA was extracted and used in assays employing primers paired with locked nucleic acid (LNA) or TaqMan probes. Droplets were generated and streamed through a droplet reader (BioRad Laboratories, CA). The QuantaSoft software (BioRad Laboratories) was used to analyze the ddPCR data. Results. In limit of detection studies, ddPCR detected 0.002 cpd of known mutant DNA in a background of 1 cpd of wt DNA. Specific KRAS mutations were detected in 16 (of 50) samples using LNA probes. Of the 16 samples tested by LNA probes, 13 were also tested using TaqMan probes, confirming results from the LNA assays. Results from ddPCR assays were compared to results from an outside commercial laboratory. The commercial lab detected and identified mutations in 10 of the 50 FFPE samples tested. ddPCR assays also detected mutations in 10 of these samples. An additional five samples were determined to be positive by commercial qPCR but no specific mutation was reported. ddPCR detected and identified specific mutations in three of these as well as in three samples not identified by commercial qPCR. Conclusions. ddPCR allele specific assays compared well to current commercially available KRAS mutation detection assays. Some cross reactivity was noted in ddPCR assays employing LNA probes but not TaqMan probes. Articles from Journal of Biomolecular Techniques : JBT are provided here courtesy of The Association of Biomolecular Resource Facilities.
机译:背景:外显子2,密码子12和13中具有KRAS突变的转移性结直肠癌(CRC)肿瘤无法从抗表皮生长因子受体(EGFR)抗体治疗中受益。当前的最佳实践建议,将CRC患者纳入KRAS突变分析作为西妥昔单抗或帕尼单抗治疗的先决条件。我们选择了50个CRC福尔马林固定石蜡包埋(FFPE)样品,以比较qPCR测定法(QIAGEN therascreen?KRAS RGQ PCR Kit)和液滴数字PCR(ddPCR)。测试了KRAS密码子12和13中的野生型和六个单核苷酸突变。方法。提取DNA并将其用于与锁定核酸(LNA)或TaqMan探针配对的引物的测定中。产生液滴并流过液滴读取器(BioRad Laboratories,CA)。使用QuantaSoft软件(BioRad Laboratories)分析ddPCR数据。结果。在检测限度内,ddPCR在1 cpd的wt DNA背景中检测到0.002 cpd的已知突变体DNA。使用LNA探针在16个样本(共50个)中检测到特定的KRAS突变。通过LNA探针测试的16个样品中,还使用TaqMan探针测试了13个样品,从而证实了LNA分析的结果。将ddPCR分析的结果与外部商业实验室的结果进行比较。商业实验室检测并鉴定了50个FFPE样品中的10个的突变。 ddPCR分析还检测了其中10个样品中的突变。通过商业qPCR确定另外五个样品为阳性,但是没有报道特异性突变。 ddPCR检测并鉴定了其中三个以及未通过商业qPCR鉴定的三个样品中的特定突变。结论。 ddPCR等位基因特异性检测与目前市售的KRAS突变检测检测相比具有优势。在使用LNA探针而不是TaqMan探针的ddPCR分析中发现了一些交叉反应。这里由生物分子资源设施协会提供了《生物分子技术杂志》上的文章:JBT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号